Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous umbilical cord blood nucleated cells
- Development stage
- Unknown
- Lead developer
- Stem Cell Institute
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous umbilical cord blood nucleated cells is an investigational cell therapy being developed by the **StemCell Institute** (Japan) for the treatment of neurodevelopmental disorders, primarily **Autism Spectrum Disorder (ASD)**. The therapy utilizes the total nucleated cell (TNC) fraction of a patient's own umbilical cord blood, which is collected at birth and cryopreserved in a cord blood bank. This cell population includes hematopoietic stem cells, mesenchymal stem cells, regulatory T cells, and other progenitor cells. When administered intravenously, these cells are hypothesized to exert therapeutic effects through paracrine signaling and immunomodulation, specifically by reducing neuroinflammation and promoting neural connectivity and repair in the brain. A Phase 2 clinical trial (jRCTb050240170) is currently evaluating the safety and efficacy of this treatment in children with ASD.
- Other names
- autologous umbilical cord blood total nucleated cellsTNCsautologous UCB-TNC
Beyond the preview
Go deeper on autologous umbilical cord blood nucleated cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous umbilical cord blood nucleated cells.